[Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease]

Gastroenterol Hepatol. 2002 Jun-Jul;25(6):401-15. doi: 10.1016/s0210-5705(02)70275-6.
[Article in Spanish]
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Azathioprine / administration & dosage
  • Azathioprine / adverse effects
  • Azathioprine / therapeutic use*
  • Chi-Square Distribution
  • Child
  • Colitis, Ulcerative / complications
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / surgery
  • Confidence Intervals
  • Crohn Disease / complications
  • Crohn Disease / drug therapy
  • Crohn Disease / surgery
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Infant, Newborn
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / surgery
  • Injections, Intravenous
  • Intestinal Fistula / drug therapy
  • Intestinal Fistula / etiology
  • Male
  • Mercaptopurine / administration & dosage
  • Mercaptopurine / adverse effects
  • Mercaptopurine / therapeutic use*
  • Mesalamine / administration & dosage
  • Mesalamine / therapeutic use
  • Meta-Analysis as Topic
  • Odds Ratio
  • Placebos
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Time Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • Placebos
  • Mesalamine
  • Mercaptopurine
  • Azathioprine